Patricia de León

Dr. Patricia de León

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Vaccine
Verified
Journal Article
Closed access
Carmina Gallardo FrontauraCarmina Gallardo Frontaura
Carmina Gallardo Frontaura
ESElena G. Sánchez
Elena G. Sánchez
DPDaniel Pérez-Núñez
Daniel Pérez-Núñez
MNMarisa Nogal
Marisa Nogal
PLPatricia de León
Patricia de León
YRYolanda Revilla
Yolanda Revilla

1 December 2011 in Current Protocols in Cell Biology
Verified
Journal Article
Open access
PDF file
ACAngel L. Carrascosa
Angel L. Carrascosa
MBM. Jose Bustos
M. Jose Bustos
PLPatricia de León
Patricia de León
Growing African swine fever virus (ASFV) isolates obtained mainly from the field, but also engineered in the laboratory, is a critical step for diagnosis, titration, or virus infection studies. This unit describes a set of methods and protocols to produce and titrate any ASFV strain in cell cultures. The procedures include (1) basic techniques to prepare virus‐sensitive target cells; (2) strategies for growth, concentration, and purification of virus stocks; and (3) the semi‐quantitative (end dilution) and quantitative (plaque) assays for the determination of viral titers, and the use of different ASFV‐sensitive cells as targets for virus production and titration. Curr. Protoc. Cell Biol. 53:26.14.1‐26.14.25. © 2011 by John Wiley & Sons, Inc.

1 April 2013 in Virus Research
Verified
Journal Article
Closed access
PLPatricia de León
Patricia de León
MBMaría J. Bustos
María J. Bustos
ACAngel L. Carrascosa
Angel L. Carrascosa

11 November 2010 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
CHCarolina Hurtado
Carolina Hurtado
MBMaria José Bustos
Maria José Bustos
AGAitor G. Granja
Aitor G. Granja
PLPatricia de León
Patricia de León
PSPrado Sabina
Prado Sabina
ACAngel L. Carrascosa
Angel L. Carrascosa

1 October 2009 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
FMFrancisco Medina
Francisco Medina
MRManuel Ramos
Manuel Ramos
Salvador IborraSalvador Iborra
Salvador Iborra
PLPatricia de León
Patricia de León
MRMarta Rodríguez-Castro
Marta Rodríguez-Castro
MVMargarita Del Val
Margarita Del Val
Most pathogen-derived peptides recognized by CD8+ CTL are produced by proteasomes and delivered to the endoplasmic reticulum by the TAP transporters associated with Ag processing. Alternative proteases also produce antigenic peptides, but their actual relevance is unclear. There is a need to quantify the contribution of these supplementary pathways in vitro and in vivo. A well-defined TAP-independent secretory route of Ag processing involves the trans-Golgi network protease furin. Quantitation of this route by using OVA constructs encoded by vaccinia viruses indicates that it provides approximately one-third of all surface complexes of peptide and MHC class I molecules. Generation of the epitope carboxyl terminus is a dramatic rate-limiting step, since bypassing it increased efficiency by at least 1000-fold. Notably, the secretory construct activated a similar percentage of Ag-specific CD8+ T cells in wild type as in TAP1-deficient mice, which allow only secretory routes but which have a 10- to 20-fold smaller CD8 compartment. Moreover, these TAP1−/− OVA-specific CD8+ T lymphocytes accomplished elimination of epitope-bearing cells in vivo. The results obtained with this experimental system underscore the potential of secretory pathways of MHC class I Ag presentation to elicit functional CD8+ T lymphocytes in vivo and support the hypothesis that noncytosolic processing mechanisms may compensate in vivo for the lack of proteasome participation in Ag processing in persons genetically deficient in TAP and thus contribute to pathogen control.

8 May 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
MFMar Forner
Mar Forner
RCRodrigo Canas-Arranz
Rodrigo Canas-Arranz
SDSira Defaus
Sira Defaus
PLPatricia de León
Patricia de León
MPMiguel Rodríguez Pulido
Miguel Rodríguez Pulido
David AndreuDavid Andreu
David Andreu
Vaccines are considered one of the greatest global health achievements, improving the welfare of society by saving lives and substantially reducing the burden of infectious diseases. However, few vaccines are fully effective, for reasons ranging from intrinsic limitations to more contingent shortcomings related, e.g., to cold chain transport, handling and storage. In this context, subunit vaccines where the essential antigenic traits (but not the entire pathogen) are presented in rationally designed fashion have emerged as an attractive alternative to conventional ones. In particular, this includes the option of fully synthetic peptide vaccines able to mimic well-defined B- and T-cell epitopes from the infectious agent and to induce protection against it. Although, in general, linear peptides have been associated to low immunogenicity and partial protection, there are several strategies to address such issues. In this review, we report the progress towards the development of peptide-based vaccines against foot-and-mouth disease (FMD) a highly transmissible, economically devastating animal disease. Starting from preliminary experiments using single linear B-cell epitopes, recent research has led to more complex and successful second-generation vaccines featuring peptide dendrimers containing multiple copies of B- and T-cell epitopes against FMD virus or classical swine fever virus (CSFV). The usefulness of this strategy to prevent other animal and human diseases is discussed.